Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Keytruda: An Extended Follow-up...

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Jun 15, 2021 2:29am

186 Views

Post# 33386775

RE:Keytruda: An Extended Follow-up...

CancerSlayer wrote:

ASCO GU 2021: Pembrolizumab for the Treatment of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Gurin: Extended Follow-up of KEYNOTE-057 Cohort A

"Overall, 101 patients received pembrolizumab and 96 were included in the efficacy analysis (five patients did not meet BCG-unresponsive criteria). The median age of patients was 73 years (range: 44-92), and patients received a median of 12.0 (range: 7.0-45.0) BCG instillations. In this updated analysis, the median time from enrollment to data cutoff date of May 25, 2020, was 36.4 months (range: 26.3-48.5). Of 96 patients, the complete response rate was 40.6% (95% confidence interval [CI] 30.7-51.1) at first evaluable disease assessment, and the median duration of response was 16.2 months (range: 0.0+ to 36.2). Among 39 responders, 13 (33.3%) remained in complete response ≥18 months and 9 (23.1%) remained in complete response ≥24 months as of the data cutoff date"

Keytruda CR summary:

CR @ first evaluable assessment = 40.6%

Maintained CR @ 12(+) months = 19%

Maintained CR @ 18(+) months = 13.5%

Maintaned CR @ 24(+) months = 9.4%

Re: CR, a relatively low bar has been set...one that is getting significantly lower with time.

Add in number of required treatments, treatment compliance & overall cost, that bar drops even further. All imo...GLTA.